Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This phase II trial studies how well lenalidomide works in treating patients with acute myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of cancer, although cancer still may be in the body and may be likely to come back or spread. Biological therapies, such as lenalidomide, use substances made from living organisms that may kill cancer cells by blocking blood flow to the cancer and by stimulating white blood cells to kill the cancer cells.
Epistemonikos ID: a2c5ba78b8d92e651454f521aaffc4b8d5ef7fa7
First added on: May 11, 2024